Enzymatics Inc. has acquired ArcherDx Inc. in a deal valued at up to $50 million.
ArcherDx, headquartered in Denver, Colo., develops software used to analyze cancer treatments.
The purchase price is made up of cash, equity and potential milestone payments.
Beverly, Mass.-based Enzymatics produces enzymes for companies that focus on nucleic acid identification. The deal allows Enzymatics to provide more services to clinical researchers and make diagnostic tests based on certain genetic mutations.
Enzymatics, founded in 2006, has raised just over $1 million from a group of angel investors led by Keswick Ventures.